Healthcare Professional Portal

Click here for prescribing information and adverse event reporting information (hosted externally).
Our Services
PI & AE

Discover QUVIVIQ™ (daridorexant), as a treatment option for adult patients with chronic insomnia1,2

QUVIVIQ™ (daridorexant) is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.1

What is QUVIVIQ™?
What is QUVIVIQ™?
How QUVIVIQ™ works?
How QUVIVIQ™ works?
Efficacy and safety
Efficacy and safety
It's not just my nights that are affected - it's my days that suffer

What does
chronic insomnia
feel like for your patients?

* For adults with chronic insomnia with symptoms lasting for 3 nights or more per week3 for at least 3 months and whose daytime functioning is considerably affected, only if CBT-I has been tried but not worked or is unavailable or unsuitable. The length of treatment should be as short as possible.3,4

Chronic insomnia topics

NICE recommends Daridorexant for treating long-term insomnia

Read the evidence-based recommendations on Daridorexant (QUVIVIQ™) for treating long-term insomnia in adults.

Read the evidence-based recommendations on Daridorexant (QUVIVIQ™) for treating long-term insomnia in adults.

  • Read NICE recommendations

Understanding chronic insomnia

Deepen your understanding of chronic insomnia

Explore a self-led course on chronic insomnia through interactive modules and case studies.

  • Start e-learning

NICE recommends Daridorexant for treating long-term insomnia

Read the evidence-based recommendations on Daridorexant (QUVIVIQ™) for treating long-term insomnia in adults.

  • Read NICE Recommandations

Practical resources

Discuss key domains to uncover your patients’ insomnia

  • Download the Resource

Patient support material from Idorsia Pharmaceuticals UK Ltd.

Summary of the two Phase 3 studies on daridorexant

  • Read the Summary

Promotional material from Idorsia Pharmaceuticals UK Ltd.

Overactive wake signalling as a cause of chronic insomnia

  • Watch the Video

Promotional material from Idorsia Pharmaceuticals UK Ltd.
...Less than 1 hour

Beyond sleepless nights: managing chronic insomnia in adults in primary care

Replay CPD hours Video
Catch up on our CPD-accredited webinar series in collaboration with MIMS Learning. Our expert speakers explore the impact of chronic insomnia in diverse patient populations, discuss diagnostic approaches and share real-life experiences with patients.

Promotional material from Idorsia Pharmaceuticals UK Ltd.

UK-DA-01116
| Date of preparation: February 2026
  • New resource
...Less than 15 min.

Vodcast series: Insomnia Uncovered

Vodcast Video
Join Dr Allie Hare, consultant in sleep medicine in London, and Dr Cameron Livingston, a GP specialising in sleep in Glasgow, over a series of 6 vodcasts, as they discuss insomnia, its impact, diagnosis and treatment.

Promotional material from Idorsia Pharmaceuticals UK Ltd.

UK-DA-00788
| Date of preparation: March 2026
  • Popular resource
...Less than 5 min.

Insomnia conversation starter

Downloadable document
This interactive questionnaire is designed to support your consultation with patients, helping to identify patients’ sleep concerns.

Patient support material from Idorsia Pharmaceuticals UK Ltd.

UK-DA-00785
| Date of preparation: March 2026

Visit our dedicated insomnia resource centre

Navigate through our collection of expert videos, engaging infographics, and essential downloads to better support your patients with chronic insomnia.

  • Access resource centre

References

  1. QUVIVIQ™ Idorsia Pharmaceuticals LTD, Summary of Product Characteristics.
  2. Mignot E, et al. Lancet Neurol. 2022. 21(2); 125–139.
  3. NICE. TA922. Daridorexant for treating long-term insomnia, October 2023. Available at: https://www.nice.org.uk/guidance/ta922. Last accessed March 2026.
  4. SMC. SMC2611. Daridorexant film-coated tablets (Quviviq®). Available at: https://www.scottishmedicines.org.uk/media/8230/daridorexant-quviviq-final-march-2024-for-website.pdf. Last accessed March 2026

This information is intended for UK healthcare professionals.

Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google play or Apple App store. Adverse events should also be reported to ds.safety.uk@idorsia.com.

UK-DA-00400 | Date of preparation: March 2026

Copyright © 2026 Idorsia Pharmaceuticals Ltd

Welcome to the Idorsia UK
Healthcare Professional Portal

This information is intended for UK Healthcare Professionals only.

By entering this site you are confirming that you are a UK Healthcare Professional.

I am a UK healthcare professional
I am a member of the public

UK-DA-00217 | Date of preparation: February 2026

Copyright ©2026 Idorsia Pharmaceuticals Ltd
Welcome back!

Please complete the form below to sign in.

You don’t have an account? 

Sign up

You are now leaving
pro.idorsia.uk

You will now be redirected to an independent third party site that is maintained outside of this website, where all Idorsia Pharmaceuticals Ltd UK’s medicines can be found: the electronic Medicines Compendium (eMC)

Continue to medicines.org.uk

UK-DA-00439 | Date of preparation: February 2026

Copyright ©2026 Idorsia Pharmaceuticals Ltd

Your resource is ready to download.

Providing your details is optional, but enables us to share future updates and resources that may be of interest to you.

Download will open in a new window.

Register and stay up to date with the latest news about QUVIVIQ™▼ (daridorexant), chronic insomnia and sleep science. By registering and ticking this box you are confirming you have read and agreed to the Informed Consent and Privacy Policy and you herewith consent to the processing of your personal data in line therewith.

You are now leaving
pro.idorsia.uk

You are now leaving pro.idorsia.uk. You will now be redirected to an independent third-party site that is maintained outside of this website.

You are now leaving pro.idorsia.uk. The linked website provides helpful information if you are having trouble sleeping. It is neither owned or controlled by Idorsia Pharmaceuticals Ltd. Idorsia accepts no responsibility for the content or services of the linked site.

Cancel
Go to link

UK-DA-00445 | Date of preparation: Februrary 2026

Copyright ©2026 Idorsia Pharmaceuticals Ltd

Confirming your contact information and preferences means that you agree that we, Idorsia, manage your personal data in our Client Relationship Management system to document, customise, plan, and conduct our interactions with you and, to analyse and segment your interactions, interests, preferences, and scientific activities in order to interact with you in a way we think is most relevant to you.

It also means that you agree that we will send you Idorsia standard or personalised medical, company or product related information and material via email based on your choices and on what we think is of interest to you. You further consent that we process your personal data for this.

For more information about us, our processing of your personal data and your rights, please see our Privacy Notice.

Create an account
Access our in-depth e-learning resources on chronic insomnia
Title *
First name *
Last name *
Professional email *
Password *
Specialty *
Professional registration number *

Select below to keep informed of further resources:

You already have an account? 

Sign in

Gain access to resources on chronic insomnia​

Register to get access to:

  • Insightful videos
  • Patient resources
  • E-Learning programme
  • And details about us and our offerings